Keeping the Workforce: the Drug Industry's Cognitive Dissonance Problem
Amidst the mounting attacks on the drug industry by respected mass market publications and broadcast news, it is growing increasingly difficult for those in the industry to maintain the personal mission of "doing good" that--at least partly--attracted them to the pharmaceutical business. In the past, attractive option packages might have helped executives deal with uneasiness about some of the strategies being pursued by companies under the gun of blockbuster economics. But with stock prices low, that source of comfort has been removed--raising doubts about the industry's ability to retain its best and brightest.
You may also be interested in...
At Windhover's annual Marketing Pharmaceutical Innovation (MPI) conference in November, industry executives wrestled with an emerging dilemma -- how to win managed care's support for drugs that exhibit only minor improvements to existing products, while new over-the-counter (OTC) options surface.
Coronavirus Notebook: EMA Issues Guidance On Development Of Variant Vaccines, EU Leaders Urge Production Ramp-Up
A batch of AstraZeneca/Oxford University coronavirus vaccines has arrived in Ghana, the first country in the world to receive vaccines via the COVAX Facility.
Scanwell Health, a leader in smartphone-enabled home diagnostics tests, has announced a partnership with Beckton Dickson.